MADDEN SECURITIES Corp Boosts Stake in GSK plc (NYSE:GSK)

MADDEN SECURITIES Corp boosted its stake in shares of GSK plc (NYSE:GSK - Free Report) by 22.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 106,830 shares of the pharmaceutical company's stock after acquiring an additional 19,400 shares during the period. GSK accounts for about 1.6% of MADDEN SECURITIES Corp's portfolio, making the stock its 16th biggest position. MADDEN SECURITIES Corp's holdings in GSK were worth $4,139,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Indiana Trust & Investment Management Co raised its position in GSK by 200.0% during the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock valued at $25,000 after purchasing an additional 500 shares in the last quarter. Sierra Ocean LLC acquired a new position in shares of GSK during the 4th quarter worth $32,000. Parkside Financial Bank & Trust lifted its position in shares of GSK by 470.1% during the 4th quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company's stock worth $34,000 after buying an additional 818 shares during the last quarter. Golden State Wealth Management LLC acquired a new stake in GSK in the fourth quarter valued at about $38,000. Finally, Lee Danner & Bass Inc. bought a new position in GSK in the fourth quarter valued at about $39,000. 15.74% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on GSK. Berenberg Bank restated a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a report on Monday, April 28th. Morgan Stanley began coverage on shares of GSK in a research note on Wednesday, February 12th. They set an "equal weight" rating for the company. Wall Street Zen downgraded GSK from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Finally, BNP Paribas assumed coverage on GSK in a research note on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price target for the company. One research analyst has rated the stock with a sell rating, nine have given a hold rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $37.38.

GSK Trading Up 1.1%

Shares of GSK stock traded up $0.44 on Tuesday, reaching $41.30. 5,087,740 shares of the company's stock were exchanged, compared to its average volume of 4,822,741. The company has a market capitalization of $84.65 billion, a P/E ratio of 25.97, a price-to-earnings-growth ratio of 1.12 and a beta of 0.52. GSK plc has a 52 week low of $31.72 and a 52 week high of $44.67. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The firm's 50-day moving average is $37.66 and its two-hundred day moving average is $36.48.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, topping analysts' consensus estimates of $1.08 by $0.05. GSK had a net margin of 8.13% and a return on equity of 48.59%. The business had revenue of $10.06 billion during the quarter, compared to analysts' expectations of $7.52 billion. During the same period last year, the company posted $0.43 earnings per share. The business's quarterly revenue was up 2.1% on a year-over-year basis. Sell-side analysts predict that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be paid a dividend of $0.4216 per share. This is an increase from GSK's previous quarterly dividend of $0.39. This represents a $1.69 dividend on an annualized basis and a yield of 4.08%. The ex-dividend date of this dividend is Friday, May 16th. GSK's dividend payout ratio is 86.60%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.